ImmunityBio (IBRX) is jumping 20% after the drug maker reported that the FDA had approved its use of an “alternative source ...

We recently published a list of 10 Stocks Stand Strong Amid Cautious Market Environment. In this article, we are going to ...

ImmunityBio (IBRX) announced the U.S. Food and Drug Administration FDA has authorized an expanded access program EAP that will bring a vital ...

CULVER CITY, Calif., February 19, 2025--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced the U.S. Food and Drug Administration (FDA) has authorized an expanded ...

D. Boral Capital restated their buy rating on shares of ImmunityBio (NASDAQ:IBRX – Free Report) in a report released on Friday,Benzinga reports. They currently have a $30.00 price target on the stock.

ImmunityBio, Inc. (NASDAQ:IBRX) is a biotechnology company working to develop therapies that enhance the immune system of patients, instead of weakening it. Since its inception in 2014 ...

ImmunityBio IBRX shares rallied 27.2% on Thursday after it announced that it has completed the regulatory filing process in the EU and the United Kingdom for Anktiva (nogapendekin alfa ...

ImmunityBio (IBRX) is jumping 20% after the drug maker reported that the FDA had approved its use of an "alternative source of BCG." Specifically, the company will now be able to provide this ...